Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

Topline data from the phase 3 ATTAIN-MAINTAIN trial evaluated orforglipron for weight maintenance after initial treatment with Wegovy or Zepbound in adults with obesity or overweight.

Lilly has a new pill, called orforglipron, it plans to launch next year. On Thursday, the company reported the results of a ...

Eli Lilly reports Phase 3 data showing oral obesity drug orforglipron maintained weight loss after Wegovy or Zepbound, beating placebo.

Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.

The average weight increase after 52 weeks for Wegovy patients was 2 pounds, whereas Zepbound patients gained 11 pounds. Eli ...

Doctors and groups representing employers said they’re increasingly hearing about companies cutting weight loss drugs out of ...

Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...

Zepbound (tirzepatide) and Wegovy (semaglutide) are FDA-approved injectable medications revolutionizing weight management. Both belong to the incretin mimetic drug class but differ in their mechanisms ...

The pills are expected to cost much less then shots of blockbuster drugs like Zepbound and Wegovy. Mr. Funk was the managing ...

Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...